India to Myanmar: Ceftazidime Export Trade Route

The India to Myanmar Ceftazidime corridor is one of India's established pharmaceutical export routes, with 24 shipments documented worth a combined $397.4K USD. The route is dominated by BIOCOLL PHARMACEUTICALS PRIVATE LIMITED, which alone accounts for roughly 48% of all export value, reflecting the consolidated nature of India's ceftazidime manufacturing sector.

Across 12 active suppliers, the average shipment value stands at $16.6K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (69%) and air (18%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during January–March, with an average transit time of 24 days port-to-port. The route has recorded an annual growth rate of 19.6%, placing it at rank #2 among India's top ceftazidime export destinations globally.

On the import side, key buyers of Indian ceftazidime in Myanmar include BIOMEDIC HEALTHCARE SOLUTION, MYIT MAHAR TRADING CO LTD, MOE THITSAR MYAY COMPANY LIMITED and 15 others. BIOMEDIC HEALTHCARE SOLUTION is the single largest importer with 2 shipments valued at $189.7K USD.

India's ceftazidime exports to Myanmar are driven primarily by a handful of large-scale manufacturers. BIOCOLL PHARMACEUTICALS PRIVATE LIMITED with 2 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 12 active exporters signals a competitive but concentrated market — buyers in Myanmar benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — BIOCOLL PHARMACEUTICALS PRIVATE LIMITED, INVEX HEALTH PRIVATE LIMITED, KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LIMITED — together account for 73% of total trade value on this route. The average shipment value of $16.6K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as tizime 1 g powder for injection-ceftazidime for injection usp 1 gm(batch no-3125037) as per invoice and tizime 1g powder for injection - (ceftazidime for injection usp 1gm) (clear glass vial in a carton box), suggesting that buyers in Myanmar tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, BIOMEDIC HEALTHCARE SOLUTION is the largest importer with 2 shipments worth $189.7K USD — representing 48% of all ceftazidime imports from India on this route. A total of 18 buyers are active on this corridor.